Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7649148 | 0.86 | HTT (0.47) | HSD11B1OPRM1CDK4CCND1 | |
| SCHEMBL7659194 | 0.84 | ALDH1A1 (0.51) | POLBOPRM1MGLLHPGDADORA2A | |
| SCHEMBL7660359 | 0.82 | MGLL (0.44) | HSD11B1OPRM1MGLLHPGDADORA2A | |
| SCHEMBL7652883 | 0.82 | OPRM1 (0.41) | OPRM1MGLLHPGDADORA2AADORA2B | |
| SCHEMBL7658070 | 0.82 | NPC1 (0.44) | MGLL | |
| SCHEMBL7656052 | 0.79 | ADORA1 (0.54) | MGLLADORA2A | |
| SCHEMBL7652545 | 0.79 | ADORA3 (0.49) | HPGDADORA2AADORA2B | |
| SCHEMBL7652262 | 0.79 | NOX4 (0.45) | POLBMAPK14MAPK11OPRM1HPGD | |
| Dimethylamine SCHEMBL7656223 | 0.78 | MGLL (0.41) | HSD11B1MAPK14OPRM1MGLLHPGD | |
| Dimethylamine SCHEMBL7652266 | 0.78 | MAPK14 (0.42) | POLBMAPK14MAPK11PDE4BCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | claimed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | claimed |
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | PARK7, IAPP, HIF1AN | HSD11B1 1050/4885POLB 1214/4885MAPK14 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.